+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Glomerulonephritis (Genitourinary Disorders) - Drugs In Development, 2021

  • PDF Icon

    Report

  • 403 Pages
  • July 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5402639
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis - Drugs In Development, 2021, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape.

Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 19, 11, 2, 29, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
Glomerulonephritis - Overview
  • Glomerulonephritis - Therapeutics Development
Glomerulonephritis - Therapeutics AssessmentGlomerulonephritis - Companies Involved in Therapeutics DevelopmentGlomerulonephritis - Drug ProfilesGlomerulonephritis - Dormant ProjectsGlomerulonephritis - Discontinued ProductsGlomerulonephritis - Product Development MilestonesAppendix
List of Tables
  • Number of Products under Development for Glomerulonephritis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Glomerulonephritis - Pipeline by Alexion Pharmaceuticals Inc, 2021
  • Glomerulonephritis - Pipeline by Algomedix Inc, 2021
  • Glomerulonephritis - Pipeline by Alnylam Pharmaceuticals Inc, 2021
  • Glomerulonephritis - Pipeline by Amyndas Pharmaceuticals LLC, 2021
  • Glomerulonephritis - Pipeline by Angion Biomedica Corp, 2021
  • Glomerulonephritis - Pipeline by Apellis Pharmaceuticals Inc, 2021
  • Glomerulonephritis - Pipeline by Biogen Inc, 2021
  • Glomerulonephritis - Pipeline by Bird Rock Bio Inc, 2021
  • Glomerulonephritis - Pipeline by Bristol Myers Squibb Co, 2021
  • Glomerulonephritis - Pipeline by Cabaletta Bio Inc, 2021
  • Glomerulonephritis - Pipeline by Calliditas Therapeutics AB, 2021
  • Glomerulonephritis - Pipeline by Cellmid Ltd, 2021
  • Glomerulonephritis - Pipeline by Certa Therapeutics Pty Ltd, 2021
  • Glomerulonephritis - Pipeline by ChemoCentryx Inc, 2021
  • Glomerulonephritis - Pipeline by Chinook Therapeutics Inc, 2021
  • Glomerulonephritis - Pipeline by Coegin Pharma AS, 2021
  • Glomerulonephritis - Pipeline by Complexa Inc, 2021
  • Glomerulonephritis - Pipeline by Cytodesign Inc, 2021
  • Glomerulonephritis - Pipeline by Delta 4 GmbH, 2021
  • Glomerulonephritis - Pipeline by DiaMedica Therapeutics Inc, 2021
  • Glomerulonephritis - Pipeline by Dimerix Ltd, 2021
  • Glomerulonephritis - Pipeline by Eledon Pharmaceuticals Inc, 2021
  • Glomerulonephritis - Pipeline by Ergon Pharmaceuticals LLC, 2021
  • Glomerulonephritis - Pipeline by Generian Pharmaceuticals Inc, 2021
  • Glomerulonephritis - Pipeline by Goldfinch Bio Inc, 2021
  • Glomerulonephritis - Pipeline by HanAll Biopharma Co Ltd, 2021
  • Glomerulonephritis - Pipeline by IGAN Biosciences Inc, 2021
  • Glomerulonephritis - Pipeline by Integral Molecular Inc, 2021
  • Glomerulonephritis - Pipeline by INVENT Pharmaceuticals Inc, 2021
  • Glomerulonephritis - Pipeline by Ionis Pharmaceuticals Inc, 2021
  • Glomerulonephritis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
  • Glomerulonephritis - Pipeline by KeyMed Biosciences Inc, 2021
  • Glomerulonephritis - Pipeline by Kiniksa Pharmaceuticals Ltd, 2021
  • Glomerulonephritis - Pipeline by Kyowa Kirin Co Ltd, 2021
  • Glomerulonephritis - Pipeline by Mallinckrodt Plc, 2021
  • Glomerulonephritis - Pipeline by MorphoSys AG, 2021
  • Glomerulonephritis - Pipeline by Novartis AG, 2021
  • Glomerulonephritis - Pipeline by NovelMed Therapeutics Inc, 2021
  • Glomerulonephritis - Pipeline by Omeros Corp, 2021
  • Glomerulonephritis - Pipeline by Oraxion Therapeutics Inc, 2021
  • Glomerulonephritis - Pipeline by Pfizer Inc, 2021
  • Glomerulonephritis - Pipeline by Polaris Pharmaceuticals Inc, 2021
  • Glomerulonephritis - Pipeline by Polyneuron Pharmaceuticals AG, 2021
  • Glomerulonephritis - Pipeline by Puretech Health Plc, 2021
  • Glomerulonephritis - Pipeline by Ra Pharmaceuticals Inc, 2021
  • Glomerulonephritis - Pipeline by Reata Pharmaceuticals Inc, 2021
  • Glomerulonephritis - Pipeline by Rohto Pharmaceutical Co Ltd, 2021
  • Glomerulonephritis - Pipeline by Rongchang Pharmaceuticals Ltd, 2021
  • Glomerulonephritis - Pipeline by Shanghai Alebund Pharmaceuticals Ltd, 2021
  • Glomerulonephritis - Pipeline by Slate Bio Inc, 2021
  • Glomerulonephritis - Pipeline by Sujana Biotech, LLC, 2021
  • Glomerulonephritis - Pipeline by Surrozen Inc, 2021
  • Glomerulonephritis - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
  • Glomerulonephritis - Pipeline by Transcenta Holding Ltd, 2021
  • Glomerulonephritis - Pipeline by Travere Therapeutics Inc, 2021
  • Glomerulonephritis - Pipeline by Vera Therapeutics Inc, 2021
  • Glomerulonephritis - Pipeline by Vertex Pharmaceuticals Inc, 2021
  • Glomerulonephritis - Pipeline by Visterra Inc, 2021
  • Glomerulonephritis - Dormant Projects, 2021
  • Glomerulonephritis - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Glomerulonephritis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Alexion Pharmaceuticals Inc
  • Algomedix Inc
  • Alnylam Pharmaceuticals Inc
  • Amyndas Pharmaceuticals LLC
  • Angion Biomedica Corp
  • Apellis Pharmaceuticals Inc
  • Biogen Inc
  • Bird Rock Bio Inc
  • Bristol Myers Squibb Co
  • Cabaletta Bio Inc
  • Calliditas Therapeutics AB
  • Cellmid Ltd
  • Certa Therapeutics Pty Ltd
  • ChemoCentryx Inc
  • Chinook Therapeutics Inc
  • Coegin Pharma AS
  • Complexa Inc
  • Cytodesign Inc
  • Delta 4 GmbH
  • DiaMedica Therapeutics Inc
  • Dimerix Ltd
  • Eledon Pharmaceuticals Inc
  • Ergon Pharmaceuticals LLC
  • Generian Pharmaceuticals Inc
  • Goldfinch Bio Inc
  • HanAll Biopharma Co Ltd
  • IGAN Biosciences Inc
  • Integral Molecular Inc
  • INVENT Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • KeyMed Biosciences Inc
  • Kiniksa Pharmaceuticals Ltd
  • Kyowa Kirin Co Ltd
  • Mallinckrodt Plc
  • MorphoSys AG
  • Novartis AG
  • NovelMed Therapeutics Inc
  • Omeros Corp
  • Oraxion Therapeutics Inc
  • Pfizer Inc
  • Polaris Pharmaceuticals Inc
  • Polyneuron Pharmaceuticals AG
  • Puretech Health Plc
  • Ra Pharmaceuticals Inc
  • Reata Pharmaceuticals Inc
  • Rohto Pharmaceutical Co Ltd
  • Rongchang Pharmaceuticals Ltd
  • Shanghai Alebund Pharmaceuticals Ltd
  • Slate Bio Inc
  • Sujana Biotech, LLC
  • Surrozen Inc
  • Takeda Pharmaceutical Co Ltd
  • Transcenta Holding Ltd
  • Travere Therapeutics Inc
  • Vera Therapeutics Inc
  • Vertex Pharmaceuticals Inc
  • Visterra Inc
  • Wuhan LL Science and Technology Development Co Ltd
  • ZyVersa Therapeutics Inc